Acadia Posts Record Q4 Revenue Growth, Announces Phase III Pipeline Starts
Acadia reported record Q4 2025 revenue growth driven by its central nervous system drug portfolio. Executives highlighted upcoming Phase III starts for two pipeline candidates and outlined expanded 2026 R&D spending plans.
1. Q4 2025 Financial Results
Acadia achieved record Q4 2025 revenue thanks to increased sales of its CNS therapies, marking a significant year-over-year gain. The company maintained its full-year profitability outlook while noting improved operating leverage.
2. Pipeline and R&D Plans
Management confirmed initiation of Phase III trials for two late-stage candidates targeting migraine and schizophrenia. The company also plans to boost 2026 R&D investments to support these pivotal studies and accelerate clinical milestones.
Related News
ELF
e.l.f. Beauty Marks 29th Consecutive Sales Growth, Reinvests $58.5M Tariff Refunds
ELF•
NVDA
Nvidia posts $81.6bn Q1 revenue, raises dividend 25-fold and authorizes $80bn buyback
NVDA•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
WPM
Wheaton Precious Metals Publishes Report Highlighting $9.4M Community Investment and MSCI AAA Rating
WPM•
EXR
Extra Space Storage Adds Retail and Tech Executives with 850-Unit Chain, Ex-Matterport CEO to Board
EXR•
Sources
F